Blood-based tumor mutational burden from circulating tumor DNA and immune checkpoint inhibitors in advanced prostate cancer.Grant Rauterkus, Mehmet Asım Bilen, Reagan M. Barnett et al.|Journal of Clinical Oncology|2022Cited by 3